The use of urine in the follow-up of hpv vaccine trials

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 2, 2015, Pages 350-352

  Vorsters, Alex ^a   Keer, Severien Van ^a   Damme, Pierre Van ^a  

^a NONE

Author keywords

HPV testing; Human papillomavirus; Urine; Vaccine efficacy trials

Indexed keywords

WART VIRUS VACCINE; VIRUS DNA;

CYTOLOGY; FOLLOW UP; HUMAN; NOTE; PAPILLOMAVIRUS INFECTION; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; PROPHYLAXIS; URINALYSIS; URINE; UTERINE CERVIX CANCER; VACCINATION; FEMALE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; VIROLOGY;

DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; URINE;

EID: 84929094262     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.995058     Document Type: Note

References (26)

1. zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 1977; 78:1-30; PMID:202434
2. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656 http://dx.doi.org/10.1016/S0140-6736(09)61248-4
3. Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garc_ıa P, et al. A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against Highgrade Cervical and External Genital Lesions. Cancer Prevention Research 2009; 2:868-78;PMID:19789295; http://dx.doi.org/10.1158/1940-6207.CAPR-09-0031
4. The FUTURE II study group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. New England Journal of Medicine 2007; 356:1915-27;PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
5. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines–immune responses. Vaccine 2012; 30 (Suppl 5):F83-7;PMID:23199968; http://dx.doi.org/10.1016/j.vaccine.2012.04.106
6. Schiller JT, Castellsagu_e X, Garland SM. A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine 2012; 30(Supplement 5):F123-F38;PMID:23199956; http://dx.doi.org/10.1016/j.vaccine.2012.04.108
7. Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines 2014; 13:1-12; PMID:25256262
8. IARC. Primay end-points for prophylactic HPV vaccine trials.Working Group Report II Series. Lyon, 2014:1-94.
9. Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez- Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years. Journal of Infectious Diseases 2009; 199:926-35; PMID: 19236279; http://dx.doi.org/10.1086/597307
10. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-55; PMID:20643092;http://dx.doi.org/10.1016/j.vaccine.2010.07.007
11. Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonz_alez P, Kreimer AR, Porras C, Schussler J, Jim_enez S, Sherman ME, et al. Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. Cancer Discovery 2011; 1:408-19; PMID:22586631;http://dx.doi.org/10.1158/2159-8290.CD-11-0131
12. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, et al. Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women. Cancer Epidemiology Biomarkers & Prevention 2010; 19:1585-94; PMID:20530494; http://dx.doi.org/10.1158/1055- 9965.EPI-09-1235
13. Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. The Lancet 2009; 373:1949-57; PMID:19493565; http://dx.doi.org/ 10.1016/S0140-6736(09)60691-7
14. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6//11//16//18 L1 virus-like particle vaccine through 5 years of followup. Br J Cancer 2006; 95:1459-66; PMID:17117182; http://dx.doi.org/10.1038/sj.bjc.6603469
15. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. 2008.
16. Khallouf H, Grabowska A, Riemer A. Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines 2014; 2:422-62; http://dx.doi.org/10.3390/vaccines2020422
17. Van Damme P. Phase I trial results with procervix vaccine in HPV 16/18 infected women with normal cytology. Abstract SS 9-4 Presented at EUROGIN Florence, Italy, 2013.
18. Fambrini M, Penna C, Pieralli A, Bussani C, Fallani MG, Andersson KL, Scarselli G, Marchionni M. PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2008; 109:59-64; PMID:18255129; http://dx.doi.org/10.1016/j.ygyno. 2007.12.032
19. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH, et al. Accuracy of human papillomavirus testing on selfcollected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014; 15:172-83; PMID:24433684; http://dx.doi.org/10.1016/S1470-2045(13)70570-9
20. Cuschieri K, Nandwani R, McGough P, Cook F, Hogg L, Robertson C, Cubie H. Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. J Med Virol 2011; 83:1983-7; PMID:21915874; http:// dx.doi.org/10.1002/jmv.22183
21. Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, Van Damme P. Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol 2012; 31:627-40; PMID:21818524; http://dx.doi.org/10.1007/s10096-011-1358-z
22. Enerly E, Olofsson C, Nygard M. Monitoring human papillomavirus prevalence in urine samples: a review. Clin Epidemiol 2013; 5:67-79; PMID:23516174; http://dx.doi.org/10.2147/CLEP.S39799
23. Kitchener HC, Owens GL. Urine testing for HPV. 2014.
24. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. 2014.
25. Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J, Hens A, De Coster I, Ieven M, Van Damme P. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis 2014; 33(11):2005-14; PMID:24916950
26. Vorsters A, Van Damme P, Clifford G. Urine testing for HPV: rationale for using first void. BMJ: BMJ, 2014; 349:g6252;PMID:25319476